Home » Stocks » IOVA

Iovance Biotherapeutics, Inc. (IOVA)

Stock Price: $30.25 USD 0.11 (0.36%)
Updated Apr 19, 2021 1:35 PM EDT - Market open
Market Cap 4.43B
Revenue (ttm) n/a
Net Income (ttm) -259.58M
Shares Out 138.30M
EPS (ttm) -1.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $30.25
Previous Close $30.14
Change ($) 0.11
Change (%) 0.36%
Day's Open 29.60
Day's Range 29.34 - 30.95
Day's Volume 1,206,357
52-Week Range 24.67 - 54.21

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Median Duration of Response Not Reached at 28.1 Months  of Median Study Follow Up in Cohort 2 of C-144-01 Study

1 week ago - GlobeNewsWire

TIL therapy looks able to win a large addressable market, and Iovance is the leader of the pack.

2 weeks ago - The Motley Fool

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?

3 weeks ago - Zacks Investment Research

SAN CARLOS, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announ...

1 month ago - GlobeNewsWire

SAN CARLOS, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announ...

1 month ago - GlobeNewsWire

With the trading day about halfway over, the broad markets were pushing higher on the day.

Other stocks mentioned: BMBL, NEE, WPM, AKBA, ARAV, BGNE, IMO ...
1 month ago - 24/7 Wall Street

SAN CARLOS, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announ...

1 month ago - GlobeNewsWire

Iovance's (IOVA) fourth-quarter earnings miss estimates. The company is progressing well with development of its lead pipeline candidate.

1 month ago - Zacks Investment Research

Advancing First-in-Class TIL Cell Therapy for Solid Tumors Advancing First-in-Class TIL Cell Therapy for Solid Tumors

1 month ago - GlobeNewsWire

SAN CARLOS, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report i...

2 months ago - GlobeNewsWire

SAN CARLOS, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...

3 months ago - GlobeNewsWire

Iovance is ramping up tumor-infiltrating lymphocytes as an ingenious way to eradicate cancers. As such, I believe it'll continue to deliver stellar data. Riding robust data, LPN-145 and lifileucel, are ...

3 months ago - Seeking Alpha

SAN CARLOS, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...

3 months ago - GlobeNewsWire

SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...

4 months ago - GlobeNewsWire

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

SAN CARLOS, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...

4 months ago - GlobeNewsWire

Iovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate.

5 months ago - Zacks Investment Research

44.4% Overall Response Rate (ORR) and Median Duration of Response (DOR) Not Reached at 8.6 Months of Study Follow Up

5 months ago - GlobeNewsWire

Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

SAN CARLOS, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report i...

5 months ago - GlobeNewsWire

In this article we are going to use hedge fund sentiment as a tool and determine whether Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a good investment right now. We like to analyze hedge fund sentime...

5 months ago - Insider Monkey

SAN CARLOS, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...

5 months ago - GlobeNewsWire

Iovance Biotherapeutics, in an attempt to secure FDA-approval for their biologic, lifileucel, in advanced melanoma, was set back as the FDA requires some more information. This can't come to much of a s...

5 months ago - Seeking Alpha

Smaller biotechs would make nice additions to pharma companies in similar areas of therapy

Other stocks mentioned: GBT, RETA
5 months ago - GuruFocus

SAN CARLOS, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...

6 months ago - GlobeNewsWire

NEW YORK, Oct. 9, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). Such investors are advis...

6 months ago - PRNewsWire

Iovance (IOVA) delays its application to the FDA for a tumor-infiltrating lymphocyte (TIL) therapy, lifileucel, for the treatment of metastaic melanoma until later in 2021.

6 months ago - Zacks Investment Research

Shares of Iovance Biotherapeutics Inc. iova were down 20.0% in premarket trading on Tuesday, the day after the biotechnology company said it plans to now submit an application to the Food and Drug Admin...

6 months ago - Market Watch

SAN CARLOS, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...

6 months ago - GlobeNewsWire

SAN CARLOS, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today provide...

6 months ago - GlobeNewsWire

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?

7 months ago - Zacks Investment Research

Iovance's (IOVA) second-quarter bottom line beats estimates. The company is progressing well with its lead pipeline candidates.

8 months ago - Zacks Investment Research

SAN CARLOS, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou...

8 months ago - GlobeNewsWire

Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Enrollment Completed in Pivotal Cohort 1 of C-145-04 Cervical Cancer Study Enrollment Completed in Pivotal Cohort 1 of C-145-04 Cervical Cancer Study

8 months ago - GlobeNewsWire

SAN CARLOS, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report...

8 months ago - GlobeNewsWire

The pandemic has put the health care industry under a global spotlight.

Other stocks mentioned: AMGN, ANTM, BMY, GH, IQV, MDT, VEEV ...
9 months ago - Kiplinger

After rumors swirled about a potential acquisition, it now appears the biopharma is transitioning to commercial operations as a standalone company.

9 months ago - The Motley Fool

Adding One More Dimension In Solid Tumor Therapy - Iovance Biotherapeutics

9 months ago - Seeking Alpha

SAN CARLOS, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou...

10 months ago - GlobeNewsWire

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?

10 months ago - Zacks Investment Research

Offering Includes Exercise in Full of the Underwriters’ Option to Purchase an Additional 2.5 Million Shares of Common Stock Offering Includes Exercise in Full of the Underwriters’ Option to Purchase an ...

10 months ago - GlobeNewsWire

Iovance Biotherapeutics (IOVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

10 months ago - Zacks Investment Research

Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up

10 months ago - GlobeNewsWire

SAN CARLOS, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immun...

10 months ago - GlobeNewsWire

The biotech company is looking to raise up to $575 million ahead of its transition to commercial-stage operations.

10 months ago - The Motley Fool

Iovance Biotherapeutics (NASDA:IOVA) shares are trading lower on Thursday, after the company announced a $500 million proposed public offering of common stock.

10 months ago - Benzinga

Iovance unveiled promising test results for a cancer treatment, but IOVA stock tumbled Thursday on a subsequent public offering. Proceeds will be used, in part, to launch the drug.

10 months ago - Investors Business Daily

SAN CARLOS, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immu...

10 months ago - GlobeNewsWire

About IOVA

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastat... [Read more...]

Industry
Biotechnology
Founded
2007
CEO
Maria Fardis
Employees
241
Stock Exchange
NASDAQ
Ticker Symbol
IOVA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price forecast is 52.00, which is an increase of 71.90% from the latest price.

Price Target
$52.00
(71.90% upside)
Analyst Consensus: Buy